Observational study of early Alzheimer's patients treated with Lecanemab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study follows a cohort of patients diagnosed with early Alzheimer's disease and mild cognitive impairment who are treated with Lecanemab, a drug that targets amyloid-beta aggregation in the brain. The study aims to assess the safety and efficacy of Lecanemab, which has shown promise in previous clinical trials. Participants will undergo evaluations to confirm amyloid pathology and will be monitored for potential adverse effects related to the treatment. The goal is to gather data that could inform future treatment protocols for Alzheimer's disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Mini-Mental State Examination (MMSE) score between 22 and 30, Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score between 0.5 and 1;
* Confirmation of positive amyloid pathology by Amyloid-PET or cerebrospinal fluid Aβ testing;
* Completion of APOE gene testing.
* Willingness to use Lecanemab.

Exclusion Criteria:

* Unable to tolerate MRI scans;
* MRI showing hemorrhagic manifestations, including \>4 microbleeds, surface iron deposition in any region, previous major hemorrhage, or potential brain lesions or vascular malformations;
* Use of anticoagulants or antiplatelet drugs, presence of hemorrhagic diseases, or any other conditions that increase the risk of central nervous system bleeding;
* With unstable physical conditions, unstable mental disorders, or those who are pregnant or breastfeeding.

Where it's running

• Affiliated Hospital, School of Medicine, Zhejiang University, China
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Yanxing Chen, M.D.
• Email: chenyanxing@zju.edu.cn
• Phone: +86 188 6840 1257

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Lecanemab Efficacy Monitoring with Gold Electrode ECL in Alzheimer’s

  This study tests how well lecanemab works in people with Alzheimer’s by using a new blood test based on mesoporous gold electrode ECL to track biomarkers.

  Recruiting Phase 4 The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Yiwu, Zhejiang · NCT07688460

• NPC-1 (parthenolide and ipriflavone) for Alzheimer's blood biomarkers

  This trial will test whether taking NPC-1 (a combination of parthenolide and ipriflavone) is safe, well tolerated, and changes blood tests linked to Alzheimer's in adults 55+ with subjective cognitive decline, mild cognitive impairment, or mild Alzheimer's who have biomarker evidence of disease.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07236190

• Near-infrared light plus lecanemab for people with mild Alzheimer's

  This trial tests whether adding near-infrared light therapy to lecanemab helps people with mild Alzheimer's disease.

  Recruiting Early Phase 1 Xuanwu Hospital, Beijing · Beijing · NCT06992804

• Support program for individuals with early-stage memory loss living alone

  This study is testing a support program for people aged 60 and older with early-stage memory loss who live alone, to see if it helps them feel better and manage their challenges through online group sessions and personalized support.

  Recruiting Arizona State University · Phoenix, Arizona · NCT06962111

• Lecanemab treatment for early-onset familial Alzheimer's disease

  This study tests if a drug called Lecanemab can help people under 65 with a family history of early-onset Alzheimer's disease feel better over 18 months.

  Recruiting at 15 sites RenJi Hospital · Beijing, China and 14 other locations · NCT06883019

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.